New Solution Gives Oncology and Rare Disease Teams a Centralized, Compliant View of Patient Consent Across the Full Therapy Journey

New White Paper from Claritas Rx Entitled “Why Consent Management is Biopharma’s Blind Spot” Now Available

SOUTH SAN FRANCISCO, Calif.: Claritas Rx, the patient journey experts, today announced Consent Clearinghouse™, a dedicated solution for standardizing and centralizing patient consent across oncology, rare disease, and specialty biopharma.

As biopharma companies navigate an increasingly complex regulatory environment, including HIPAA, GDPR, CCPA, a growing patchwork of state privacy laws, and the emerging rules governing the use of AI, managing patient consent across multiple data sources, specialty pharmacies, hubs, and channel partners has become a critical operational and compliance challenge. Consent Clearinghouse addresses this directly by providing a single, auditable source of truth for consent data across all touchpoints.

Consent Clearinghouse integrates consent data from across a brand's ecosystem, including hubs, specialty pharmacies, field reimbursement managers, copay programs, and IOD/IDN channels, into a unified dashboard. Commercial and market access teams gain real-time visibility into consent status, enabling them to act on data with confidence while reducing compliance risk.

"Commercial and market access teams can no longer afford to operate on fragmented consent data - the pace of AI-driven engagement has raised the stakes too high. Real-time visibility into consent status isn't just about reducing compliance risk today; it's about building the trust infrastructure that will define how brands responsibly scale patient engagement tomorrow," said Michael Fitzgibbons, CEO of Claritas Rx. "We built Consent Clearinghouse to give biopharma teams the visibility and control they need to operate compliantly, move faster, and ultimately serve more patients. This is particularly critical for patients in oncology and rare disease who can’t afford delays caused by missing or mismanaged consent."

Key Consent Clearinghouse capabilities include:

• Unified consent tracking across all patient touchpoints and data sources
• Real-time dashboard providing consent status visibility at the patient, brand, and channel level
• Audit-ready reporting to support HIPAA, GDPR, CCPA, and state privacy compliance
• Seamless integration with existing CRM, hub, and specialty pharmacy platforms
• Role-based access controls to protect sensitive patient data across teams and partners

With experience supporting numerous brands across oncology, rare, and specialty therapeutic areas, Claritas Rx designed Consent Clearinghouse specifically for the complex, high-stakes environment of specialty and rare disease therapies, where patient access barriers and compliance requirements are greatest.

Consent and Compliance Thought Leadership

Consent management is no longer just a compliance issue; it is a patient access issue. Claritas Rx's new white paper, "Why Consent Management is Biopharma’s Blind Spot," breaks down where consent gaps form, what they cost, and how leading biopharma teams are building a more unified, audit-ready approach across the full therapy journey.

A companion webinar, “The Hidden Risk in Your Access Strategy: Rethinking Patient Consent Management,” will take place on August 19 at 10 am PT (1 pm ET). Media may request a copy of the white paper or registration to the webinar by contacting Emily Brennan.

About Claritas Rx

Based in South San Francisco, CA, Claritas Rx helps rare disease and specialty brands remove the barriers that keep patients from accessing and staying on the treatments they need. By uniting the most complete view of the patient journey with purpose-built technologies, we predict and resolve access challenges before they disrupt care. Our intelligent solutions combine advanced analytics, real-world data, AI, and in-line CRM capabilities to increase start and refill rates, reduce abandonment, and improve brand performance. For more information, visit www.ClaritasRx.com.

Fonte: Business Wire